A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Stopped The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.

Conditions

• Breast Cancer

Interventions

• DRUG: Taselisib
• DRUG: Placebo
• DRUG: Fulvestrant

Sponsor

Hoffmann-La Roche